U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07528352) titled 'External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL' on April 07.
Brief Summary: The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Diffuse Large B Cell Lymphoma
Intervention:
DRUG: Epcoritamab
Epcoritamab will be administered per standard of care.
DRUG: Glofitamab
Glofitamab will be administered per standard of care.
RADIATION: External Beam Radiation Ther...